Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found. The results suggest that a full 4‐week induction of esketamine with an oral antidepressant may optimize treatment outcomes, the researchers stated. Results of the analysis were published online July 20, 2021, in the Journal of Clinical Psychiatry.